En

It is a new receptor drug for the treatment of nutritional dystrophy and protein-energy deficiency (PEM) in cattle, sheep and goats.

A new prescription drug for normalization of protein-energy deficiency and stimulation of muscle mass growth in pigs.

Our company

We are a young but rapidly growing company that was founded in 2020. Bringing our innovative products to the global market helps the company contribute to finding solutions to some of the major livestock problems faced worldwide.

More

Our products

It is a new receptor drug for the treatment of nutritional dystrophy and protein-energy deficiency (PEM) in cattle, sheep and goats.

More

A new prescription drug for normalization of protein-energy deficiency (BEN) and stimulation of muscle mass growth in pigs.

More

Honesty and straightforwardness

Each employee maintains the highest ethical standards and acts to protect and comply with the policies and procedures necessary to produce quality pharmaceutical products.

Quality and safety

The company is committed to producing safe and effective products and providing reliable information and services to our partners. We also have strict guidelines for all our stakeholders to ensure that CSR is maintained in accordance with the corporate culture.

Innovation and continuous improvement

Each employee promotes and supports continuous efforts that lead to improvements in our processes, products, services and workplace.

Events and news

2 February 2024

Miosta Group® received a registration certificate for localization of production

More
17 January 2024

Launch of Miosta Group® telegram bot

More
12 January 2024

Research with the Samarkand Veterinary Institute

More